Reducing unnecessary antiparkinson medication in antinsychotic therapy.
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D006801:Humans; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000188:drug therapy
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents